Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07423585 · ClinicalTrials.gov registry record · Phase 2

Tarlatamab for the Treatment of Extensive Stage Small-cell Lung Cancer

A Phase 2 study of Extensive Stage Lung Small Cell Carcinoma, sponsored by Asrar Alahmadi.

Recruiting
Registry status
Phase 2
Development phase
39
Enrollment target
1
Study location

NCT07423585 is a Phase 2 study of Extensive Stage Lung Small Cell Carcinoma that is actively recruiting participants, run by Asrar Alahmadi. The registered enrollment target is 39 participants, below the 149-participant average among 16 other Extensive Stage Lung Small Cell Carcinoma trials with a reported enrollment target (74% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07423585, a Phase 2 study of Extensive Stage Lung Small Cell Carcinoma, is actively recruiting participants, sponsored by Asrar Alahmadi.

RECRUITING
Registry status
Phase 2
Development phase
39 participants
Enrollment target
1
Study location

Study Summary

This phase II trial tests the effect of tarlatamab in treating patients with small cell lung cancer (SCLC) that has spread from where it first started to other parts of the body (extensive-stage). SCLC is an aggressive cancer which has a low 5-year survival rate. Tarlatamab is a bispecific antibody that can bind to two different antigens at the same time. Tarlatamab binds to DLL3 which is a protein found on the surface of some types of tumor cells, including small-cell lung cancer, and to CD3 which is present on immune system T-cells (a type of white blood cell) and may interfere with the ability of tumor cells to grow and spread. This may increase the length of time to progression (growing, spreading, or getting worse) and help patients with extensive-stage SCLC live longer.

Conditions Studied

Extensive Stage Lung Small Cell Carcinoma

Interventions

  • PROCEDURE Biospecimen Collection
  • PROCEDURE Computed Tomography
  • PROCEDURE Biopsy Procedure
  • PROCEDURE Echocardiography Test
  • OTHER Electronic Health Record Review

Study Locations (1)

Ohio

  • Ohio State University Comprehensive Cancer Center - Columbus

Trial Details

FieldValue
Enrollment Target 39 participants
Start Date 2026-04-01
Est. Completion 2027-12-31
Phase Phase 2

Sponsor

Asrar Alahmadi

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07423585

The ClinicalTrials.gov registry entry for NCT07423585 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 149-participant average among 16 other Extensive Stage Lung Small Cell Carcinoma trials with a reported enrollment target (74% lower). The listed sponsor is Asrar Alahmadi, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Extensive Stage Lung Small Cell Carcinoma appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.

NCT07423585 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.

Frequently Asked Questions

What is clinical trial NCT07423585 about?

NCT07423585 is a clinical study titled "Tarlatamab for the Treatment of Extensive Stage Small-cell Lung Cancer". This phase II trial tests the effect of tarlatamab in treating patients with small cell lung cancer (SCLC) that has spread from where it first started to other parts of the body (extensive-stage). SCLC is an aggressive cancer which has a low 5-year survival rate. Tarlatamab is a bispecific antibody ...

What is the current status of trial NCT07423585?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 39 participants. The study started on 2026-04-01. Estimated completion is 2027-12-31.

What conditions does trial NCT07423585 study?

This clinical trial studies the following conditions: Extensive Stage Lung Small Cell Carcinoma.

What interventions are being tested in trial NCT07423585?

The interventions under investigation include: Biospecimen Collection (PROCEDURE), Computed Tomography (PROCEDURE), Biopsy Procedure (PROCEDURE), Echocardiography Test (PROCEDURE), Electronic Health Record Review (OTHER).

Who is sponsoring clinical trial NCT07423585?

This trial is sponsored by Asrar Alahmadi, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07423585 being conducted?

This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Extensive Stage Lung Small Cell Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Extensive Stage Lung Small Cell Carcinoma

All registered trials for this condition

Ohio

All trials with a study site in Ohio

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.